These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Selegiline for Parkinson's disease. Calesnick B Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624 [TBL] [Abstract][Full Text] [Related]
5. New mechanisms of action of irreversible monoamine oxidase type B inhibitors. Li XM; Juorio AV; Paterson IA; Boulton AA J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757 [No Abstract] [Full Text] [Related]
6. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
7. The multiple actions of selegiline. Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521 [No Abstract] [Full Text] [Related]
9. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. LeWitt PA Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310 [No Abstract] [Full Text] [Related]
10. [Monoamine oxidase inhibitors: prospects for the use in clinical practice]. Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260 [No Abstract] [Full Text] [Related]
11. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Lew MF Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
14. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy. Chan-Palay V Adv Neurol; 1993; 60():438-46. PubMed ID: 8093581 [No Abstract] [Full Text] [Related]
15. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
16. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Fernandez HH; Chen JJ Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen JJ; Swope DM J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398 [TBL] [Abstract][Full Text] [Related]
19. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors]. Maki Y Hokkaido Igaku Zasshi; 2001 May; 76(3):133-42. PubMed ID: 11481866 [TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease. Youdim MB; Finberg JP; Wajsbort J Prog Med Chem; 1984; 21():137-67. PubMed ID: 6400134 [No Abstract] [Full Text] [Related] [Next] [New Search]